HUE036929T2 - Alfa-folátreceptor elleni ellenanyagok és alkalmazásuk - Google Patents
Alfa-folátreceptor elleni ellenanyagok és alkalmazásukInfo
- Publication number
- HUE036929T2 HUE036929T2 HUE12736054A HUE12736054A HUE036929T2 HU E036929 T2 HUE036929 T2 HU E036929T2 HU E12736054 A HUE12736054 A HU E12736054A HU E12736054 A HUE12736054 A HU E12736054A HU E036929 T2 HUE036929 T2 HU E036929T2
- Authority
- HU
- Hungary
- Prior art keywords
- antibodies
- folate receptor
- alpha folate
- alpha
- receptor
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/56—Staging of a disease; Further complications associated with the disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161508444P | 2011-07-15 | 2011-07-15 | |
| US201261604412P | 2012-02-28 | 2012-02-28 | |
| US201261604954P | 2012-02-29 | 2012-02-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE036929T2 true HUE036929T2 (hu) | 2018-08-28 |
Family
ID=46516898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE12736054A HUE036929T2 (hu) | 2011-07-15 | 2012-07-13 | Alfa-folátreceptor elleni ellenanyagok és alkalmazásuk |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US8475795B2 (enExample) |
| EP (2) | EP2731972B1 (enExample) |
| JP (2) | JP6220333B2 (enExample) |
| CN (2) | CN107011439B (enExample) |
| AU (3) | AU2012284321C1 (enExample) |
| BR (1) | BR112014001030A2 (enExample) |
| CA (1) | CA2841725C (enExample) |
| CY (1) | CY1120600T1 (enExample) |
| DK (1) | DK2731972T3 (enExample) |
| ES (2) | ES2824498T3 (enExample) |
| HR (1) | HRP20180353T1 (enExample) |
| HU (1) | HUE036929T2 (enExample) |
| LT (1) | LT2731972T (enExample) |
| PL (1) | PL2731972T3 (enExample) |
| PT (1) | PT2731972T (enExample) |
| RS (1) | RS56985B1 (enExample) |
| SG (1) | SG10201605278PA (enExample) |
| SI (1) | SI2731972T1 (enExample) |
| SM (1) | SMT201800150T1 (enExample) |
| TR (1) | TR201802838T4 (enExample) |
| WO (1) | WO2013012722A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI672318B (zh) | 2010-02-24 | 2019-09-21 | 美商免疫遺傳股份有限公司 | 葉酸受體１抗體類和免疫共軛物類及彼等之用途 |
| CN114441757A (zh) | 2011-04-01 | 2022-05-06 | 伊缪诺金公司 | 用于增加folr1癌症治疗的功效的方法 |
| CN107011439B (zh) * | 2011-07-15 | 2020-11-10 | 卫材R&D管理有限公司 | 抗叶酸受体α抗体及其应用 |
| PL2890717T3 (pl) | 2012-08-31 | 2020-08-10 | Immunogen, Inc. | Testy i zestawy diagnostyczne do wykrywania receptora folianu |
| US20160311921A1 (en) | 2013-06-20 | 2016-10-27 | Morphotek ,Inc. | Methods for treatment of ovarian cancer |
| CN105814079B (zh) | 2013-08-30 | 2021-02-09 | 伊缪诺金公司 | 用于检测叶酸受体1的抗体和测定 |
| JP6875129B2 (ja) * | 2014-05-08 | 2021-05-19 | ノボダイアックス， インコーポレイテッド | 直接的な免疫組織化学アッセイ |
| RS61010B1 (sr) | 2014-11-20 | 2020-11-30 | Hoffmann La Roche | Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3 |
| BR112017010513A2 (pt) | 2014-11-20 | 2018-04-03 | F. Hoffmann-La Roche Ag | ?cadeias leves comuns e métodos de uso? |
| RU2753902C2 (ru) | 2014-11-20 | 2021-08-24 | Ф.Хоффманн-Ля Рош Аг | Комбинированная терапия на основе активирующих т-клетки биспецифических антигенсвязывающих молекул против cd3 и фолатного рецептора 1 (folr1) и антагонистов, связывающихся с осью pd-1 |
| RU2718780C9 (ru) * | 2015-04-17 | 2020-07-08 | Эйсай Инк. | Способы лечения рака легкого |
| KR102700777B1 (ko) | 2015-09-17 | 2024-08-29 | 이뮤노젠 아이엔씨 | 항-folr1 면역접합체를 포함하는 치료제 조합 |
| US20180236098A1 (en) | 2016-08-12 | 2018-08-23 | L.E.A.F. Holdings Group Llc | Alpha and gamma-d polyglutamated antifolates and uses thereof |
| AU2017308159B2 (en) | 2016-08-12 | 2023-08-10 | L.E.A.F. Holdings Group Llc | Polyglutamated antifolates and uses thereof |
| US10822410B2 (en) | 2016-11-23 | 2020-11-03 | Eisai R&D Management Co., Ltd. | Anti-folate receptor alpha antibodies and uses thereof |
| CN107353325B (zh) * | 2017-07-26 | 2020-08-11 | 中国药科大学 | 叶酸受体α特异性结合肽1及其应用 |
| CN107793471B (zh) * | 2017-07-26 | 2020-08-11 | 中国药科大学 | 叶酸受体α特异性结合肽4及其应用 |
| CN107446021B (zh) * | 2017-07-26 | 2020-08-11 | 中国药科大学 | 叶酸受体α特异性结合肽5及其应用 |
| CN107446020B (zh) * | 2017-07-28 | 2019-10-01 | 中国药科大学 | 叶酸受体α特异性结合肽2及其应用 |
| IL272840B2 (en) * | 2017-09-05 | 2025-01-01 | Immunogen Inc | Methods for detecting folate receptor 1 in a patient sample |
| CN111954530A (zh) | 2018-02-07 | 2020-11-17 | L.E.A.F.控股集团公司 | γ聚谷氨酸化培美曲塞及其用途 |
| EP3749319A4 (en) | 2018-02-07 | 2022-06-22 | L.E.A.F Holdings Group LLC | TETRAHYDROFOLATES ALPHA POLYGLUTAMATE AND THEIR USES |
| EP3749312A4 (en) | 2018-02-07 | 2022-02-23 | L.E.A.F Holdings Group LLC | ALPHA-POLYGLUTAMATED LOMETREXOLE AND USES THEREOF |
| JP7487107B2 (ja) | 2018-02-07 | 2024-05-20 | エル．イー．エー．エフ． ホールディングス グループ エルエルシー | アルファポリグルタミン酸化葉酸代謝拮抗薬およびその使用 |
| CA3090384A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated aminopterin and uses thereof |
| EP3749316A4 (en) | 2018-02-07 | 2021-10-27 | L.E.A.F Holdings Group LLC | ALPHA-POLYGLUTAMATED PRALATREXATE AND USES THEREOF |
| US12220431B2 (en) | 2018-02-07 | 2025-02-11 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated antifolates and uses thereof |
| CA3090391A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated raltitrexed and uses thereof |
| CN111954531A (zh) | 2018-02-07 | 2020-11-17 | L.E.A.F.控股集团公司 | α聚谷氨酸化培美曲塞及其用途 |
| WO2019157125A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated methotrexate and uses thereof |
| CA3090389A1 (en) | 2018-02-07 | 2019-08-15 | L.E.A.F. Holdings Group Llc | Alpha polyglutamated raltitrexed and uses thereof |
| CA3090875A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated lometrexol and uses thereof |
| US12048766B2 (en) | 2018-02-14 | 2024-07-30 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated tetrahydrofolates and uses thereof |
| WO2019160733A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated methotrexate and uses thereof |
| WO2019160736A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated pralatrexate and uses thereof |
| CA3090943A1 (en) | 2018-02-14 | 2019-08-22 | L.E.A.F. Holdings Group Llc | Gamma polyglutamated aminopterin and uses thereof |
| CN115925952A (zh) | 2018-03-13 | 2023-04-07 | 东莞凡恩世生物医药有限公司 | 抗叶酸受体1抗体及其用途 |
| KR102275930B1 (ko) * | 2018-03-14 | 2021-07-12 | (주)알테오젠 | Folr1에 특이적으로 결합하는 항체 및 그의 용도 |
| JP7623939B2 (ja) * | 2018-07-09 | 2025-01-29 | マルチチュード インコーポレーテッド | 葉酸受容体アルファに特異的な抗体 |
| CN111393528B (zh) * | 2020-01-19 | 2023-01-31 | 中国药科大学 | 一种靶向叶酸受体α的单链抗体及其应用 |
| US20230210989A1 (en) * | 2020-06-03 | 2023-07-06 | Kar Muthumani | Monoclonal Antibody Against Human Siglec-9 and Use For Immunotherapy |
| JP2024522544A (ja) * | 2021-06-04 | 2024-06-21 | イミュノジェン， インコーポレイテッド | 可溶性ＦＲ－α患者におけるがんの治療 |
| WO2023009529A2 (en) | 2021-07-28 | 2023-02-02 | Trustees Of Boston University | Novel polypeptides and uses thereof |
| KR20240162569A (ko) * | 2022-03-25 | 2024-11-15 | 자임워크스 비씨 인코포레이티드 | 항-엽산 수용체 알파 항체 및 사용 방법 |
| WO2024104431A1 (zh) * | 2022-11-16 | 2024-05-23 | 迈威(上海)生物科技股份有限公司 | 一种靶向FRα的抗体或其抗原结合片段及其应用 |
| AU2024305352A1 (en) | 2023-06-12 | 2025-12-04 | Amgen Inc. | Lymphotoxin beta receptor agonist binding proteins |
| CN117700557B (zh) * | 2024-02-05 | 2024-04-30 | 卡秋(江苏)生物科技有限公司 | 一种特异性结合叶酸受体α的抗体或抗原结合片段 |
| CN117700556B (zh) * | 2024-02-05 | 2024-04-12 | 苏州百道医疗科技有限公司 | 一种抗FRα小鼠单克隆抗体及其应用 |
| CN120554514B (zh) * | 2025-07-29 | 2025-12-05 | 合肥综合性国家科学中心大健康研究院 | 一种靶向人的叶酸受体α的单克隆抗体 |
| CN120842412B (zh) * | 2025-09-23 | 2025-12-05 | 合肥综合性国家科学中心大健康研究院 | 一种靶向人的叶酸受体α的单克隆抗体及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5646253A (en) | 1994-03-08 | 1997-07-08 | Memorial Sloan-Kettering Cancer Center | Recombinant human anti-LK26 antibodies |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6770445B1 (en) | 1999-02-26 | 2004-08-03 | Pacific Northwest Research Institute | Methods and compositions for diagnosing carcinomas |
| US7270960B2 (en) | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
| WO2004082463A2 (en) | 2003-03-17 | 2004-09-30 | Medical College Of Ohio | Folate receptor gene modulation for cancer diagnosis and therapy |
| US20040235108A1 (en) | 2003-05-23 | 2004-11-25 | Luigi Grasso | Monoclonal antibodies that specifically bind a tumor antigen |
| AU2005214331B2 (en) | 2004-02-12 | 2011-09-15 | Eisai, Inc. | Monoclonal antibodies that specifically bind to folate receptor alpha |
| AU2006230219A1 (en) | 2005-03-30 | 2006-10-05 | Endocyte, Inc. | Method for cancer prognosis using cellular folate vitamin receptor quantification |
| AU2006241099B2 (en) * | 2005-04-22 | 2012-04-19 | Eisai, Inc. | Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells |
| EP1900752A1 (en) * | 2006-09-15 | 2008-03-19 | DOMPE' pha.r.ma s.p.a. | Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma |
| US7754698B2 (en) | 2007-01-09 | 2010-07-13 | Isis Pharmaceuticals, Inc. | Modulation of FR-alpha expression |
| FR2918994B1 (fr) | 2007-07-20 | 2012-10-19 | Rhodia Operations | Formulations de diesters d'acide carboxylique et leur utilisation pour le traitement de materiaux. |
| WO2009132081A2 (en) | 2008-04-24 | 2009-10-29 | The Research Foundation Of State University Of New York | Monoclonal antibody-based targeting of folate receptors |
| US20110177525A1 (en) | 2010-01-19 | 2011-07-21 | Predictive Biosciences, Inc. | Antibodies and methods of diagnosing diseases |
| WO2012061759A2 (en) | 2010-11-05 | 2012-05-10 | Morphotek Inc. | Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers |
| EP2680839A1 (en) | 2011-03-02 | 2014-01-08 | Morphotek, Inc. | Co -administration of eribulin and farletuzumab for the treatment of breast cancer |
| CN107011439B (zh) * | 2011-07-15 | 2020-11-10 | 卫材R&D管理有限公司 | 抗叶酸受体α抗体及其应用 |
-
2012
- 2012-07-13 CN CN201611025725.1A patent/CN107011439B/zh active Active
- 2012-07-13 HU HUE12736054A patent/HUE036929T2/hu unknown
- 2012-07-13 PL PL12736054T patent/PL2731972T3/pl unknown
- 2012-07-13 WO PCT/US2012/046672 patent/WO2013012722A1/en not_active Ceased
- 2012-07-13 EP EP12736054.3A patent/EP2731972B1/en active Active
- 2012-07-13 AU AU2012284321A patent/AU2012284321C1/en active Active
- 2012-07-13 HR HRP20180353TT patent/HRP20180353T1/hr unknown
- 2012-07-13 RS RS20180252A patent/RS56985B1/sr unknown
- 2012-07-13 US US13/548,775 patent/US8475795B2/en active Active
- 2012-07-13 TR TR2018/02838T patent/TR201802838T4/tr unknown
- 2012-07-13 SM SM20180150T patent/SMT201800150T1/it unknown
- 2012-07-13 DK DK12736054.3T patent/DK2731972T3/en active
- 2012-07-13 SG SG10201605278PA patent/SG10201605278PA/en unknown
- 2012-07-13 BR BR112014001030A patent/BR112014001030A2/pt not_active Application Discontinuation
- 2012-07-13 ES ES17196948T patent/ES2824498T3/es active Active
- 2012-07-13 CN CN201280043606.2A patent/CN103998467B/zh active Active
- 2012-07-13 SI SI201231234T patent/SI2731972T1/en unknown
- 2012-07-13 PT PT127360543T patent/PT2731972T/pt unknown
- 2012-07-13 JP JP2014520368A patent/JP6220333B2/ja active Active
- 2012-07-13 CA CA2841725A patent/CA2841725C/en active Active
- 2012-07-13 ES ES12736054.3T patent/ES2663556T3/es active Active
- 2012-07-13 EP EP17196948.8A patent/EP3330291B1/en active Active
- 2012-07-13 LT LTEP12736054.3T patent/LT2731972T/lt unknown
-
2013
- 2013-03-13 US US13/800,575 patent/US8834877B2/en active Active
-
2014
- 2014-08-04 US US14/451,044 patent/US9599621B2/en active Active
-
2017
- 2017-02-16 US US15/434,326 patent/US10101343B2/en active Active
- 2017-04-11 AU AU2017202365A patent/AU2017202365B2/en active Active
- 2017-09-29 JP JP2017190224A patent/JP6526143B2/ja active Active
-
2018
- 2018-03-01 CY CY181100260T patent/CY1120600T1/el unknown
- 2018-09-26 AU AU2018236755A patent/AU2018236755B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE036929T2 (hu) | Alfa-folátreceptor elleni ellenanyagok és alkalmazásuk | |
| HUS2100034I1 (hu) | ANGPTL3-ellenes antitestek és alkalmazásaik | |
| HUS2100032I1 (hu) | Helyettesített 5-fluor-1H-pirazolopiridin-származékok és alkalmazásuk | |
| IL288203B (en) | Meditopes and meditope-binding antibodies and uses thereof | |
| HUS2000056I1 (hu) | ANTI-PD-L1 ellenanyagok és alkalmazásaik | |
| HUE045656T2 (hu) | PHF-tau elleni ellenanyagok és alkalmazásuk | |
| HUE044591T2 (hu) | Anti-CD40 antitestek és alkalmazásuk | |
| HUE053720T2 (hu) | ROR-1 fehérje elleni terápiás antitestek és eljárások alkalmazásukra | |
| BR112013012782A2 (pt) | anticorpos humanos para o receptor de glucagon | |
| HUE037700T2 (hu) | OX40-hez kötõdõ ellenanyagok és felhasználásuk | |
| HUE13746964T2 (hu) | CD47 antitestek és alkalmazási eljárásaik | |
| HUE054055T2 (hu) | Opoid receptor ligandumok és eljárás azok alkalmazására és elõállítására | |
| ME03075B (me) | Prolaktin receptor vezujući proteini i njihova upotreba | |
| EP2723766A4 (en) | COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR | |
| EP2723367A4 (en) | Glucagon/glp-1 receptor co-agonists | |
| DK2997134T3 (da) | Human anvendelse af genmanipulerede kimære antigenreceptor-(car)-t-celler | |
| BR112014012137A2 (pt) | anticorpos anti-fgfr2 e suas utilizações | |
| IL231777A0 (en) | Antibodies against tl1a and uses thereof | |
| HUE057004T2 (hu) | CD277 elleni antitestek és alkalmazásaik | |
| IL229951B (en) | Antibodies against epidermal growth factor receptor (egfr) and uses thereof | |
| HRP20181457T1 (hr) | Anti-htra1 protutijela i postupci uporabe | |
| DK2914291T3 (da) | Anti-komplement-c1s-antistoffer og anvendelser deraf | |
| DK3381943T3 (da) | Anti-kit-antistoffer og anvendelser deraf | |
| DK2668210T3 (da) | Anti-kit antistoffer og anvendelser deraf | |
| IL229963A0 (en) | Substituted quinolines and their use as medicaments |